IMPACT results show potential cancer treatment

Apr 19, 2010

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

"This study shows a potential new treatment paradigm in oncology and is the first active to demonstrate improvement in overall survival (OS) for metastatic CRPC (castrate-resistant prostate cancer)," said Shore

Shore said the effect was upheld with longer follow-up and that the majority of the most common adverse events occurred within one day of infusion, were mild and moderate in severity ( < grade 2) and resolved within one to two days.

"Response rate and time to progression may not be appropriate endpoints in therapeutic vaccine trials," Shore said, adding that the use of immune therapy earlier in the natural history of the disease requires further study.

Sipuleucel-T is an investigational autologous active cellular immunotherapy for treatment of . The randomised, double-blind, placebo controlled phase III trial in CRPC showed a significant increase in OS. Adverse events reported more commonly in the sipuleucel-T than the placebo arm included chills, pyrexia, headache, influenza- like illness, myalgia, hypertension, hyperhidrosis and groin pain.

Other findings indicate that prognostic factors were well-balanced with the median predicted OS of patients in the sipuleucel-T and placebo arms were 20.3 and 21.2 months, respectively, using the Halabi model (2003).

Explore further: Body Mass Index associated with breast cancer, regardless of body shape

Provided by European Association of Urology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Recommended for you

Physicians target the genes of lung, colon cancers

3 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

DNA alternative to Pap smear sparks medical debate (Update)

21 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

HIV+ women respond well to HPV vaccine

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...